Sanofi (SNY)
After hours:
| Previous Close | 49.00 |
| Open | 48.69 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 48.44 - 48.83 |
| 52 Week Range | 42.63 - 55.72 |
| Volume | |
| Avg. Volume | 2,003,300 |
| Market Cap | 121.965B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 24.77 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.04 (4.20%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | N/A |
- Zacks
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
- Reuters
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
- Associated Press Finance
Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit
A Hawaii court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding the companies failed to disclose the efficacy and safety of the medication, the state attorney general said Tuesday. The judgement was issued against Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi. Bristol Myers Squibb and Sanofi said in a joint statement they disagreed with the penalty and plan to appeal.
